Maxim Jacobs on Attitude Shift Towards Pharma Products

Director of Research at Edison Group, Maxim Jacobs speaks on the attitude shift towards pharmaceutical products.

“In other areas, the regulators are getting friendlier to anything associated with the drug culture. For example, psilocybin which is the active ingredient in magic mushrooms. The FDA approved a Phase 2B trial for the treatment of depression. So, things are changing, it’s all very interesting.” – Maxim Jacobs, Director of Research at Edison Group